• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较Healthentia软件即服务(SaMD)在慢性病管理中的临床结果:一项系统文献综述

Benchmarking the clinical outcomes of Healthentia SaMD in chronic disease management: a systematic literature review comparison.

作者信息

Kyriazakos Sofoklis, Pnevmatikakis Aristodemos, Kostopoulou Konstantina, Ferrière Laurent, Thibaut Kyun, Giacobini Erika, Pastorino Roberta, Gorini Marco, Fenici Peter

机构信息

Innovation Sprint srl, Clos Chapelle-aux-Champs, Brussels, Belgium.

COVARTIM, Watermael-Boitsfort, Belgium.

出版信息

Front Public Health. 2024 Dec 24;12:1488687. doi: 10.3389/fpubh.2024.1488687. eCollection 2024.

DOI:10.3389/fpubh.2024.1488687
PMID:39776481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11703908/
Abstract

BACKGROUND

Software as a Medical Device (SaMD) and mobile health (mHealth) applications have revolutionized the healthcare landscape in the areas of remote patient monitoring (RPM) and digital therapeutics (DTx). These technological advancements offer a range of benefits, from improved patient engagement and real-time monitoring, to evidence-based personalized treatment plans, risk prediction, and enhanced clinical outcomes.

OBJECTIVE

The systematic literature review aims to provide a comprehensive overview of the status of SaMD and mHealth apps, highlight the promising results, and discuss what is the potential of these technologies for improving health outcomes.

METHODS

The research methodology was structured in two phases. In the first phase, a search was conducted in the EuropePMC (EPMC) database up to April 2024 for systematic reviews on studies using the PICO model. The study population comprised individuals afflicted by chronic diseases; the intervention involved the utilization of mHealth solutions in comparison to any alternative intervention; the desired outcome focused on the efficient monitoring of patients. Systematic reviews fulfilling these criteria were incorporated within the framework of this study. The second phase of the investigation involved identifying and assessing clinical studies referenced in the systematic reviews, followed by the synthesis of their risk profiles and clinical benefits.

RESULTS

The results are rather positive, demonstrating how SaMDs can support the management of chronic diseases, satisfying patient safety and performance requirements. The principal findings, after the analysis of the extraction table referring to the 35 primary studies included, are: 24 studies (68.6%) analyzed clinical indications for type 2 diabetes mellitus (T2DM), six studies (17.1%) analyzed clinical indications for cardiovascular conditions, three studies (8.7%) analyzed clinical indications for cancer, one study (2.8%) analyzed clinical indications for chronic obstructive pulmonary disease (COPD), and one study (2.8%) analyzed clinical indications for hypertension. No severe adverse events related to the use of mHealth were reported in any of them. However, five studies (14.3%) reported mild adverse events (related to hypoglycemia, uncontrolled hypertension), and four studies (11.4%) reported technical issues with the devices (related to missing patient adherence requirements, Bluetooth unsuccessful pairing, and poor network connections). For what concerns variables of interest, out of the 35 studies, 14 reported positive results on the reduction of glycated hemoglobin (HbA1c) with the use of mHealth devices. Eight studies examined health-related quality of life (HRQoL); in three cases, there were no statistically significant differences, while the groups using mHealth devices in the other five studies experienced better HRQoL. Seven studies focused on physical activity and performance, all reflecting increased attention to physical activity levels. Six studies addressed depression and anxiety, with mostly self-reported benefits observed. Four studies each reported improvements in body fat and adherence to medications in the mHealth solutions arm. Three studies examined blood pressure (BP), reporting reduction in BP, and three studies addressed BMI, with one finding no statistically significant change and two instead BMI reduction. Two studies reported significant weight/waist reduction and reduced hospital readmissions. Finally, individual studies noted improvements in sleep quality/time, self-care/management, six-minute walk distance (6MWD), and exacerbation outcomes.

CONCLUSION

The systematic literature review demonstrates the significant potential of software as a medical device (SaMD) and mobile health (mHealth) applications in revolutionizing chronic disease management through remote patient monitoring (RPM) and digital therapeutics (DTx). The evidence synthesized from multiple systematic reviews and clinical studies indicates that these technologies, exemplified by solutions like Healthentia, can effectively support patient monitoring and improve health outcomes while meeting crucial safety and performance requirements. The positive results observed across various chronic conditions underscore the transformative role of digital health interventions in modern healthcare delivery. However, further research is needed to address long-term efficacy, cost-effectiveness, and integration into existing healthcare systems. As the field rapidly evolves, continued evaluation and refinement of these technologies will be essential to fully realize their potential in enhancing patient care and health management strategies.

摘要

背景

软件即医疗设备(SaMD)和移动健康(mHealth)应用已经彻底改变了远程患者监测(RPM)和数字疗法(DTx)领域的医疗格局。这些技术进步带来了一系列益处,从提高患者参与度和实时监测,到基于证据的个性化治疗方案、风险预测以及改善临床结果。

目的

本系统文献综述旨在全面概述SaMD和mHealth应用的现状,突出有前景的结果,并讨论这些技术在改善健康结果方面的潜力。

方法

研究方法分为两个阶段。在第一阶段,截至2024年4月在欧洲生物医学中心(EPMC)数据库中进行搜索,以查找使用PICO模型的系统评价研究。研究人群包括慢性病患者;干预措施是与任何替代干预措施相比使用mHealth解决方案;期望的结果侧重于对患者的有效监测。符合这些标准的系统评价被纳入本研究框架。调查的第二阶段涉及识别和评估系统评价中引用的临床研究,然后综合其风险概况和临床益处。

结果

结果相当积极,表明SaMD如何能够支持慢性病管理,满足患者安全和性能要求。在分析了涉及35项纳入的主要研究的提取表后,主要发现如下:24项研究(68.6%)分析了2型糖尿病(T2DM)的临床适应症,6项研究(17.1%)分析了心血管疾病的临床适应症,3项研究(8.7%)分析了癌症的临床适应症,1项研究(2.8%)分析了慢性阻塞性肺疾病(COPD)的临床适应症,1项研究(2.8%)分析了高血压的临床适应症。其中没有一项报告与使用mHealth相关的严重不良事件。然而,5项研究(14.3%)报告了轻度不良事件(与低血糖、高血压控制不佳有关),4项研究(11.4%)报告了设备的技术问题(与患者依从性要求缺失、蓝牙配对不成功和网络连接不佳有关)。关于感兴趣的变量,在35项研究中,14项报告使用mHealth设备在降低糖化血红蛋白(HbA1c)方面有积极结果。8项研究考察了健康相关生活质量(HRQoL);在3例中没有统计学显著差异,而在其他5项研究中使用mHealth设备的组的HRQoL更好。7项研究关注身体活动和表现,均反映出对身体活动水平的关注度增加。6项研究涉及抑郁和焦虑,大多观察到自我报告的益处。4项研究分别报告了mHealth解决方案组在身体脂肪和药物依从性方面的改善。3项研究考察了血压(BP),报告血压降低,3项研究涉及体重指数(BMI),1项发现没有统计学显著变化,另外2项则是BMI降低。2项研究报告体重/腰围显著降低以及住院再入院率降低。最后,个别研究指出在睡眠质量/时间、自我护理/管理、6分钟步行距离(6MWD)和病情加重结果方面有所改善。

结论

系统文献综述表明,软件即医疗设备(SaMD)和移动健康(mHealth)应用在通过远程患者监测(RPM)和数字疗法(DTx)彻底改变慢性病管理方面具有巨大潜力。从多个系统评价和临床研究中综合的证据表明,以Healthentia等解决方案为代表的这些技术能够在满足关键安全和性能要求的同时,有效支持患者监测并改善健康结果。在各种慢性病中观察到的积极结果凸显了数字健康干预在现代医疗服务中的变革性作用。然而,需要进一步研究来解决长期疗效、成本效益以及融入现有医疗系统的问题。随着该领域迅速发展,持续评估和完善这些技术对于充分实现其在加强患者护理和健康管理策略方面的潜力至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/010d671df025/fpubh-12-1488687-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/2471a1b6b1f1/fpubh-12-1488687-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/2d2c9db86748/fpubh-12-1488687-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/07df9b6ba765/fpubh-12-1488687-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/36c6b0f5ca0a/fpubh-12-1488687-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/89dffbea660e/fpubh-12-1488687-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/010d671df025/fpubh-12-1488687-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/2471a1b6b1f1/fpubh-12-1488687-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/2d2c9db86748/fpubh-12-1488687-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/07df9b6ba765/fpubh-12-1488687-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/36c6b0f5ca0a/fpubh-12-1488687-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/89dffbea660e/fpubh-12-1488687-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c6/11703908/010d671df025/fpubh-12-1488687-g006.jpg

相似文献

1
Benchmarking the clinical outcomes of Healthentia SaMD in chronic disease management: a systematic literature review comparison.比较Healthentia软件即服务(SaMD)在慢性病管理中的临床结果:一项系统文献综述
Front Public Health. 2024 Dec 24;12:1488687. doi: 10.3389/fpubh.2024.1488687. eCollection 2024.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.
4
Digital interventions for the management of chronic obstructive pulmonary disease.数字干预措施在慢性阻塞性肺疾病管理中的应用。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD013246. doi: 10.1002/14651858.CD013246.pub2.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.用于 1 型和 2 型成年糖尿病患者群体的持续皮下胰岛素输注(CSII)泵:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(20):1-58. Epub 2009 Oct 1.
7
Intervention and Evaluation of Mobile Health Technologies in Management of Patients Undergoing Chronic Dialysis: Scoping Review.移动医疗技术在慢性透析患者管理中的干预和评估:范围综述。
JMIR Mhealth Uhealth. 2020 Apr 3;8(4):e15549. doi: 10.2196/15549.
8
The Effectiveness of Self-Management Mobile Phone and Tablet Apps in Long-term Condition Management: A Systematic Review.自我管理手机和平板应用程序在长期疾病管理中的有效性:一项系统综述。
J Med Internet Res. 2016 May 16;18(5):e97. doi: 10.2196/jmir.4883.
9
The Effectiveness of Medical Adherence Mobile Health Solutions for Individuals With Epilepsy: Protocol for a Systematic Review.医疗依从性移动健康解决方案对癫痫患者的有效性:系统评价方案。
JMIR Res Protoc. 2024 Aug 6;13:e55123. doi: 10.2196/55123.
10
Features, outcomes, and challenges in mobile health interventions for patients living with chronic diseases: A review of systematic reviews.移动医疗干预在慢性病患者中的特点、结果和挑战:系统评价综述。
Int J Med Inform. 2019 Dec;132:103984. doi: 10.1016/j.ijmedinf.2019.103984. Epub 2019 Oct 5.

引用本文的文献

1
Multidomain Behavioral Change Digital Coaching for Chronic Disease Management in Patients With Type 2 Diabetes: Framework Development and Preliminary Evaluation.2型糖尿病患者慢性病管理的多领域行为改变数字辅导:框架开发与初步评估
JMIR Form Res. 2025 Jul 9;9:e73807. doi: 10.2196/73807.
2
Management, Safety, and Efficacy Evaluation of Nutraceutical and Functional Food: A Global Perspective.营养保健品和功能性食品的管理、安全性及功效评估:全球视角
Compr Rev Food Sci Food Saf. 2025 Jul;24(4):e70222. doi: 10.1111/1541-4337.70222.
3
Approved trends and product characteristics of digital therapeutics in four countries.

本文引用的文献

1
Telehealth care and remote monitoring strategies in heart failure patients: A systematic review and meta-analysis.心力衰竭患者的远程医疗保健与远程监测策略:一项系统评价与荟萃分析。
Heart Lung. 2024 Mar-Apr;64:149-167. doi: 10.1016/j.hrtlng.2024.01.003. Epub 2024 Jan 18.
2
The effectiveness of mobile application for monitoring diabetes mellitus and hypertension in the adult and elderly population: systematic review and meta-analysis.移动应用程序在监测成年和老年人口糖尿病和高血压中的有效性:系统评价和荟萃分析。
BMC Health Serv Res. 2023 Aug 12;23(1):855. doi: 10.1186/s12913-023-09879-6.
3
Effectiveness of Telemedicine for Reducing Cardiovascular Risk: A Systematic Review and Meta-Analysis.
四个国家数字疗法的获批趋势和产品特点。
NPJ Digit Med. 2025 May 26;8(1):308. doi: 10.1038/s41746-025-01660-9.
远程医疗降低心血管风险的有效性:一项系统评价与荟萃分析
J Clin Med. 2023 Jan 20;12(3):841. doi: 10.3390/jcm12030841.
4
Effects of mobile health interventions on health-related outcomes in older adults with type 2 diabetes: A systematic review and meta-analysis.移动医疗干预对 2 型糖尿病老年患者健康相关结局的影响:系统评价和荟萃分析。
J Diabetes. 2023 Jan;15(1):47-57. doi: 10.1111/1753-0407.13346. Epub 2023 Jan 17.
5
Effectiveness of mHealth Interventions in the Control of Lifestyle and Cardiovascular Risk Factors in Patients After a Coronary Event: Systematic Review and Meta-analysis.移动医疗干预措施在控制冠心病事件后患者生活方式和心血管危险因素中的效果:系统评价和荟萃分析。
JMIR Mhealth Uhealth. 2022 Dec 2;10(12):e39593. doi: 10.2196/39593.
6
Effectiveness of Mobile Application for Promotion of Physical Activity Among Newly Diagnosed Patients of Type II Diabetes - A Randomized Controlled Trial.移动应用程序对新诊断的II型糖尿病患者身体活动促进作用的有效性——一项随机对照试验
Int J Prev Med. 2022 Apr 5;13:54. doi: 10.4103/ijpvm.IJPVM_92_20. eCollection 2022.
7
The Clinical Effects of Type 2 Diabetes Patient Management Using Digital Healthcare Technology: A Systematic Review and Meta-Analysis.使用数字医疗技术管理2型糖尿病患者的临床效果:系统评价与Meta分析
Healthcare (Basel). 2022 Mar 13;10(3):522. doi: 10.3390/healthcare10030522.
8
Smartphone applications for physical activity and sedentary behaviour change in people with cardiovascular disease: A systematic review and meta-analysis.智能手机应用程序对心血管疾病患者身体活动和久坐行为改变的影响:系统评价和荟萃分析。
PLoS One. 2021 Oct 11;16(10):e0258460. doi: 10.1371/journal.pone.0258460. eCollection 2021.
9
Effectiveness of Telemonitoring for Reducing Exacerbation Occurrence in COPD Patients With Past Exacerbation History: A Systematic Review and Meta-Analysis.远程监测对减少有既往加重史的慢性阻塞性肺疾病患者急性加重发生的有效性:一项系统评价和荟萃分析。
Front Med (Lausanne). 2021 Sep 10;8:720019. doi: 10.3389/fmed.2021.720019. eCollection 2021.
10
Effect of a Smartphone-Based App on the Quality of Life of Patients With Heart Failure: Randomized Controlled Trial.基于智能手机的应用程序对心力衰竭患者生活质量的影响:随机对照试验。
JMIR Nurs. 2020 Nov 2;3(1):e20747. doi: 10.2196/20747.